Newsfeeds - Spark Newswire

1 minute read

Earnings

Earnings Outlook For MorphoSys

Today, 6:08 AM

MorphoSys (NASDAQ:MOR) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement. Analysts estimate that MorphoSys will report an earnings per share (EPS) of $-0.73.

MOR

1 minute read

MorphoSys Discontinues US Discovery Activities, Takes €231M Impairment Charge

By Vandana Singh

Today, 6:08 AM

MorphoSys AG (NASDAQ:MOR) has reported a non-cash impairment charge of €231 million on goodwill after consolidating research and discovery functions. This…

MOR

32 minute read

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 6:08 AM

On Monday, 524 stocks hit new 52-week lows.

AAL

22 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 6:08 AM

On Friday, 368 stocks hit new 52-week lows.

AAL

30 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 6:08 AM

During Tuesday's trading, 505 companies set new 52-week lows.

ACRX

19 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 6:08 AM

On Friday, 313 companies hit new 52-week lows.

AAON

10 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 6:08 AM

On Thursday, 147 companies achieved new lows for the year.

AFRM

1 minute read

Morgan Stanley Downgrades MorphoSys to Equal-Weight

By Benzinga Newsdesk

Today, 6:08 AM

Morgan Stanley analyst James Quigley downgrades MorphoSys (NASDAQ:MOR) from Overweight to Equal-Weight.

MOR

32 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 6:08 AM

On Thursday, 615 stocks hit new 52-week lows.

AAOI

2 minute read

20 Stocks Moving in Wednesday’s Pre-Market Session

By Lisa Levin

Today, 6:08 AM

Gainers BioRestorative Therapies, Inc. (NASDAQ: BRTX) rose 48.1% to $6.77 in pre-market trading after the company entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO), to conduct BioRestorative's Phase 2 trial.

ACST